Straits Research released its highly anticipated report, “Global Stem Cell Assays Market Size & Outlook, 2026-2034”. According to this study, the market size is valued at USD 3.28 billion in 2025 and is projected to expand to USD 11.29 billion by 2034, registering a compound annual growth rate (CAGR) of 14.76%.
The global stem cell assays market is expanding steadily as research institutions, biopharmaceutical companies, and clinical laboratories increase their focus on regenerative medicine and drug discovery. A primary driver of this growth is the accelerating investment in stem cell-based research for developing novel therapeutics, toxicity screening platforms, and personalized medicine solutions. As chronic diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions rise worldwide, researchers increasingly rely on stem cell assays to evaluate cell function, proliferation, differentiation, and viability, strengthening their role in early-stage drug development.
Despite this upward momentum, the market is restrained by the high cost and technical complexity associated with stem cell assay development and execution. These assays often require specialized instrumentation, high-purity reagents, and advanced laboratory expertise, making them expensive for smaller research facilities. At the same time, an important opportunity lies in the growing shift toward automation screening and induced pluripotent stem cell technologies. These innovations enable more efficient assay workflows, reduce manual variability, and expand the use of stem cell models for precision medicine applications. As automated platforms mature and iPSC-derived cell lines become more accessible, the market is expected to benefit from increased scalability and wider commercial adoption.
October 2025: REPROCELL Europe Ltd. launched the Alvetex plasticware platform designed to expand the capabilities of 3D cell culture and bioengineered tissue models.